These two British drugs behemoths are similar businesses that both pay big dividends, and they’ve mostly tended to move in lockstep. However, in recent months GlaxoSmithKline (LSE: GSK) has sported a much higher — and hence more potentially more attractive — yield than AstraZeneca (LSE: AZN). So what’s up? Owain Bennallack investigates…
Should you buy AstraZeneca PLC shares today?
Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from Trump's tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.
That's why this could be an ideal time to secure this valuable research – Mark's analysts have scoured the markets to reveal 5 of his favourite long-term 'Buys'. Please, don't make any big decisions before seeing them.